Table 1 Characteristics of Included Studies and Patients of the Meta-Analysis
Trial, First Author, year | Active treatment | Imaging Modality | Setting | N° Patients | Age | Males (%) | FU (mo) | LV Remodeling Indices | Beta-blockers, (%) | ACEi/ARBs/ARNI, (%) |
|---|---|---|---|---|---|---|---|---|---|---|
SUGAR-DM-HF trial Lee Matthew MY, 2021 | Empagliflozin | CMR | HFrEF | 92 | 69±11 | 73 | 9 | EDV, EDVi, ESV, ESVi, EF, LVMi, | 91 | 100 |
EMPA-TROPISM, Santos-Gallego CG et al., 2021 | Empagliflozin | CMR | HFrEF | 80 | 62±12 | 64 | 6 | EDV, ESV, EF, LVM | 88 | 85 |
EMPIRE-HF, Omar Massar et al., 2021 | Canagliflozin | Echo | HFrEF | 179 | 64±11 | 85 | 3 | EDV, EDVi, ESV, ESVi, EF, LVMi, | 95 | 100 |
The REFORM Trial, Singh JSS et al., 2020 | Dapagliflozin | CMR | HFrEF | 56 | 67±7 | 66 | 12 | EDV, EDVi, ESV, ESVi, EF, LVMi | 82 | 89 |
CANA-HF, Carbone S, 2020 | Canagliflozin | Echo | HFrEF | 36 | 56±7 | 78 | 3 | EDVi, ESVi, EF, NTproBNP | 94 | 86 |
EMMY Trial Von Lewinski D et al., 2022 | Empagliflozin | Echo | HFrEF | 476 | 58±9 | 82 | 6.5 | EDV, EDVi ESV, ESVi, EF, NTproBNP | 96 | 98 |
EXCEED Trial, Akasaka H et al., 2020 | Ipragliflozin | Echo | HFpEF | 68 | 71±8 | 60 | 6 | EDV, ESV, EF, LVMi | NA | NA |
CANDLE Trial, Tanaka A. et al., 2020 | Canagliflozin | Echo | HFrEF, HFpEF | 233 | 69±10 | 75 | 6 | EF, NTproBNP | 70 | 76 |
MUSCAT-HF, Ejiri K. et al., 2020 | Luseogliflozin | Echo | HFpEF | 165 | 73±7 | 62 | 3 | EF, LVMi, NTproBNP | 61 | 59 |